Membrane-bound proteindisulfide isomerase (PDI) is involved in regulation of surface expression of thiols and drug sensitivity of B-CLL
A few reviews have been published regarding CD10 appearance in B-cell CLL, however the actual frequency about CD10 expression in cases on CLL/SLL is not known.20,21 Kampalath et al studied the prognostic significance of CD10 in CLL/SLL and reported a comparatively higher frequency of 10.3%.22 The CD11c is a marker of acute myelomonocytic leukemia; it was the most common aberrant marker observed in about 17% B-CLL
SLL accounts for less than 10% of overt malignancy, and for this reason B-CLL
is most commonly used to represent both variants (CLL/SLL) (6,8-17).
Stratification of B-CLL
patients participating in the current study into distinct subgroups with similar prognosis based on established prognostic factors followed by Kaplan-Meier OS analysis was also performed.
In addition, 67% (14/21) of patients demonstrated 64% to 75% CD200 loss on B-CLL
cells following the first dose of samalizumab, which may represent CD200 down-modulation or CD200+ cell loss.
The potent activity of monoglycerides toward leukemic cell lines prompted examination whether these compounds would be as efficient in primary leukemic cells, such as leukemic B cells from patients suffering from B-CLL
. Notably, monoglycerides triggered dose -dependent death in B cells from B-CLL
patients, whereas PBMCs (peripheral blood mononuclear cells) from healthy individuals treated with the same concentrations remained unaffected, even after a 24-hour incubation .
In a separate development, the drug MabCampath for patients with B-cell chronic lymphocytic leukaemia (B-CLL
), has been approved for use in Wales by the AWMSG.
The new indication is for first-line treatment of B-cell chronic lymphocytic leukemia (B-CLL
), the leading form of adult leukemia.
Kolmogorov-Smimov statistical test for analysis of ZAP-70 expression in B-CLL
, compared with quantitative PCR and IgV(H) mutation status.
The microenvironment around tumors plays an important role in cell survival and growth in B-cell chronic leukocytic leukemia (B-CLL
HuMax-CD20 (ofatumumab), a fully human monoclonal antibody, is in late stage development for CD20 positive B-cell chronic lymphocytic leukemia (B-CLL
) and follicular non-Hodgkin's lymphoma (NHL), and in Phase II for rheumatoid arthritis (RA).
Campath is co-marketed by the Genzyme Corporation, Cambridge, MA, and Berlex, Inc., a unit of German-based Schering AG, and is currently FDA-approved to treat a type of leukemia, B-cell chronic lymphocytic leukemia B-CLL